BGI Genomics and Roche Diagnostics have rolled out tests for Alzheimer's disease in China, the companies said, in an effort ...

Roche expects filing for up to three new molecular entities in 2026, and accelerating its pipeline through partnerships and ...

MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of ...

If you are wondering whether Roche Holding is still an attractive opportunity after its recent run, or whether that value is already reflected in the price, this article will walk through what the ...

Roche is a relative latecomer to GLP-1 metabolic disorder drugs, but an oral drug candidate that came as part of a $2.7 billion acquisition last year now has preliminary early-stage clinical data that ...

Roche has removed eight phase 1 and 2 oncology and neurology candidates from its pipeline as part of a set of “trade-offs” intended to “increase the overall portfolio value and speed up development.” ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in its ...

Unable to sell its plant in Clarecastle, Ireland, Roche will take a wrecking ball to the facility in June. It won’t be a simple process. In fact, a timeline of June 2021 to May 2028 has been listed ...

Roche’s gene therapy ambitions have taken another blow. Shortly after writing down (PDF) the value of one of Spark Therapeutics’ hemophilia A candidates, the Swiss drugmaker has removed a second ...